Equities analysts expect Retrophin Inc (NASDAQ:RTRX) to report sales of $44.00 million for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Retrophin’s earnings, with the highest sales estimate coming in at $44.50 million and the lowest estimate coming in at $43.10 million. Retrophin reported sales of $42.18 million in the same quarter last year, which would indicate a positive year over year growth rate of 4.3%. The company is expected to report its next earnings results on Tuesday, February 26th.
On average, analysts expect that Retrophin will report full year sales of $164.42 million for the current fiscal year, with estimates ranging from $163.50 million to $164.90 million. For the next fiscal year, analysts forecast that the company will post sales of $184.10 million, with estimates ranging from $173.50 million to $194.00 million. Zacks’ sales averages are a mean average based on a survey of research analysts that cover Retrophin.
Retrophin (NASDAQ:RTRX) last announced its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.39). Retrophin had a negative net margin of 69.38% and a negative return on equity of 35.43%. The firm had revenue of $40.70 million during the quarter, compared to analyst estimates of $44.36 million. During the same quarter in the previous year, the business posted $0.15 EPS. Retrophin’s revenue for the quarter was up 1.0% compared to the same quarter last year.
Shares of NASDAQ RTRX traded down $1.28 during mid-day trading on Friday, reaching $25.77. 208,500 shares of the company traded hands, compared to its average volume of 336,830. Retrophin has a fifty-two week low of $20.09 and a fifty-two week high of $33.00. The company has a debt-to-equity ratio of 0.60, a current ratio of 5.04 and a quick ratio of 4.99. The firm has a market capitalization of $1.07 billion, a PE ratio of -17.18 and a beta of 1.19.
In other Retrophin news, CEO Steve Aselage sold 12,000 shares of Retrophin stock in a transaction that occurred on Friday, August 31st. The shares were sold at an average price of $32.00, for a total value of $384,000.00. Following the transaction, the chief executive officer now owns 257,883 shares in the company, valued at $8,252,256. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders own 3.67% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the business. Principal Financial Group Inc. grew its position in Retrophin by 10.1% in the first quarter. Principal Financial Group Inc. now owns 21,228 shares of the biopharmaceutical company’s stock worth $475,000 after buying an additional 1,950 shares during the last quarter. MetLife Investment Advisors LLC grew its position in Retrophin by 14.9% in the second quarter. MetLife Investment Advisors LLC now owns 18,842 shares of the biopharmaceutical company’s stock worth $514,000 after buying an additional 2,439 shares during the last quarter. State Board of Administration of Florida Retirement System grew its position in Retrophin by 11.7% in the second quarter. State Board of Administration of Florida Retirement System now owns 26,595 shares of the biopharmaceutical company’s stock worth $725,000 after buying an additional 2,790 shares during the last quarter. Meeder Asset Management Inc. grew its position in Retrophin by 315.6% in the third quarter. Meeder Asset Management Inc. now owns 4,663 shares of the biopharmaceutical company’s stock worth $135,000 after buying an additional 3,541 shares during the last quarter. Finally, California Public Employees Retirement System grew its position in Retrophin by 7.3% in the second quarter. California Public Employees Retirement System now owns 56,525 shares of the biopharmaceutical company’s stock worth $1,541,000 after buying an additional 3,824 shares during the last quarter.
Retrophin, Inc, a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.
Read More: Leveraged Buyout (LBO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.